Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7637207 | 1.00 | CYP1A2 (0.36) | CYP1A2NOS1NOS2CNR1CNR2 | |
| SCHEMBL7641220 | 1.00 | CYP1A2 (0.36) | CYP1A2NOS1NOS2CNR1CNR2 | |
| SCHEMBL7637436 | 1.00 | CYP1A2 (0.36) | CYP1A2NOS1NOS2CNR1CNR2 | |
| SCHEMBL7637444 | 1.00 | CYP1A2 (0.36) | CYP1A2NOS1NOS2CNR1CNR2 | |
| SCHEMBL7640459 | 0.99 | CYP1A2 (0.33) | CYP1A2NOS1NOS2 | |
| SCHEMBL7640452 | 0.99 | CYP1A2 (0.33) | CYP1A2NOS1NOS2 | |
| SCHEMBL7640444 | 0.94 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL7640440 | 0.94 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL7637074 | 0.88 | — | — | |
| SCHEMBL7638591 | 0.85 | NOS3 (0.30) | NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482966-B2 | REDUCING A CROSSLINK-CYCLIZED CYCLOPENTANONE WITH AN ALKALI METAL HYDRIDE, AND THEN REATING THE RESULTING CROSSLINK-CYCLIZED CYCLOPENTENOL IS WITH A DEHYDRATING AGENT | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20010012902-A1 | Crosslink-cyclized cyclopentadiene and dihalobis type metal compound containing same as ligand | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| EP-1122229-A1 | Process for the preparation of condensed cyclopentadiene derivatives, 1, 3 disubstituted derivatives and metallocene type compounds containing them as ligand | HONSHU CHEMICAL INDUSTRY CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012902-A1 | Crosslink-cyclized cyclopentadiene and dihalobis type metal compound containing same as ligand | CYC1, DCLRE1A, PPIL1 | CYP1A2 444/4885NOS1 1253/4885NOS2 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.